India’s apex drug regulator, the Central Drugs Standard Control Organisation (CDSCO), has formally implemented a prior intimation mechanism under amendments to the New Drugs and Clinical Trials Rules 2019, significantly easing the process for manufacturing new drugs for testing and analysis.

The reform replaces the earlier requirement of obtaining a test licence with a simpler, trust-based system. Pharmaceutical companies can now begin manufacturing small quantities of new or investigational drugs for analytical and non-clinical purposes by submitting an online intimation and receiving an acknowledgment from the Central Licensing Authority.

Introduced through amendments to the New Drugs and Clinical Trials Rules 2019, the reform was notified on January 17, 2026, and has been made operational from April 21, 2026.

As per the official order issued by CDSCO on April 20, 2026, the move is part of broader amendments notified in January 2026 aimed at reducing regulatory bottlenecks and improving ease of doing business in India’s pharmaceutical and clinical research ecosystem.

By eliminating the need for prior approvals in low-risk scenarios, the reform is expected to significantly shorten drug development timelines and reduce administrative burden. 

Under the earlier framework, companies were required to secure a test licence from CDSCO before manufacturing drugs for research, examination, or analysis—a process that often led to delays. The new system is expected to save up to 90 days in the development cycle, allowing faster progression from discovery to preclinical evaluation. 

However, the prior intimation pathway does not apply universally. High-risk categories, including cytotoxic drugs, sex hormones, beta-lactam antibiotics, biologics containing live microorganisms, and narcotic or psychotropic substances, will continue to require prior regulatory approval to ensure safety and compliance. 

The reform also aligns with India’s push toward digital governance, with applications and acknowledgments processed through integrated online platforms such as the National Single Window System. This digital-first approach is expected to improve transparency, traceability, and efficiency in regulatory workflows.